Nothing Special   »   [go: up one dir, main page]

CA2395999A1 - Methode permettant d'identifier des ligands de molecules biologiques cibles - Google Patents

Methode permettant d'identifier des ligands de molecules biologiques cibles Download PDF

Info

Publication number
CA2395999A1
CA2395999A1 CA002395999A CA2395999A CA2395999A1 CA 2395999 A1 CA2395999 A1 CA 2395999A1 CA 002395999 A CA002395999 A CA 002395999A CA 2395999 A CA2395999 A CA 2395999A CA 2395999 A1 CA2395999 A1 CA 2395999A1
Authority
CA
Canada
Prior art keywords
protein
receptors
binding
biological target
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002395999A
Other languages
English (en)
Inventor
Christian E. Elling
Birgitte Holst Lange
Lars Ole Gerlach
Thue W. Schwartz
Jan Torleif Pedersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
7TM Pharma AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2395999A1 publication Critical patent/CA2395999A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une approche moléculaire permettant d'identifier rapidement et sélectivement de petits ligands de molécules organiques, c'est-à-dire des composés capables d'interagir avec des sites spécifiques et de se lier à ceux-ci sur des molécules biologiques cibles. Les méthodes de cette invention peuvent s'appliquer à toute molécule biologique cible qui a été manipulée ou peut l'être, de façon à posséder un site de liaison métal-ion. Les molécules biologiques cibles sont, par exemple des protéines, des polypeptides, des oligopeptides, des acides nucléiques, des carbohydrates, des nucléoprotéines, des glycoprotéines, des glycolipides, des lipoprotéines et des dérivés de ceux-ci. De manière plus spécifique, les molécules biologiques cibles comprennent des récepteurs membranaires, des protéine de transduction de signal, des protéines d'assemblage, des récepteurs nucléaires, des récepteurs de stéroïde, des récepteurs intracellulaires, des facteurs de transcription, des enzymes, des protéines régulatrices d'enzyme allostérique, des facteurs de croissance, des hormones, des neuropeptides et des immunoglobulines. Un groupe de molécules biologiques cibles très intéressant est constitué par des protéines membranaires telles que, par exemple, des protéines transmembranaires (par exemple, 7 TM). La méthode décrite ci-dessus permet de construire et d'analyser des bibliothèques de composés spécifiquement dirigés contre des épitopes prédétermines sur les molécules biologiques cibles. Les composés sont initialement construits pour être bifonctionnels, c'est-à-dire pour posséder à la fois une fraction de liaison métal-ion qui les transporte, leur permettant de se lier à un site de liaison métal-ion construit soit naturellement soit artificiellement, et une fraction variable qui varie chimiquement, de façon à détecter des interactions avec des parties spécifiques de la molécule biologique ciblée située spatiallement adjacente au site de liaison métal-ion. Lesdits composés peuvent ensuite être modifiés de façon à se lier à la molécule biologique cible non modifiée sans l'aide du pontage métal-ion. Les méthodes de l'invention peuvent s'exécuter rapidement et facilement et conduire à des résultats non équivoques. Les composés identifiés à l'aide desdites méthodes peuvent s'utiliser dans différentes applications ou peuvent être dérivés ou modifiés de façon à obtenir de nouveaux composés.
CA002395999A 1999-12-30 2000-12-29 Methode permettant d'identifier des ligands de molecules biologiques cibles Abandoned CA2395999A1 (fr)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
DK199901879 1999-12-30
DK199901880 1999-12-30
DKPA199901879 1999-12-30
DKPA199901880 1999-12-30
US17599400P 2000-01-11 2000-01-11
US17540100P 2000-01-11 2000-01-11
US60/175,994 2000-01-11
US60/175,401 2000-01-11
DKPA200000705 2000-04-28
DK200000705 2000-04-28
US20299000P 2000-05-09 2000-05-09
US60/202,990 2000-05-09
PCT/EP2000/013389 WO2001050127A2 (fr) 1999-12-30 2000-12-29 Methode permettant d'identifier des ligands de molecules biologiques cibles

Publications (1)

Publication Number Publication Date
CA2395999A1 true CA2395999A1 (fr) 2001-07-12

Family

ID=27545201

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002395999A Abandoned CA2395999A1 (fr) 1999-12-30 2000-12-29 Methode permettant d'identifier des ligands de molecules biologiques cibles

Country Status (4)

Country Link
EP (1) EP1242824A2 (fr)
AU (1) AU2844901A (fr)
CA (1) CA2395999A1 (fr)
WO (1) WO2001050127A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003003008A1 (fr) * 2001-06-29 2003-01-09 7Tm Pharma A/S Bibliotheques chimiques utiles aux procedes de decouvertes de medicaments
WO2003003009A1 (fr) * 2001-06-29 2003-01-09 7Tm Pharma A/S Utilisation de chelates a ions metalliques dans la validation de molecules biologiques utilisees comme cibles medicamenteuses dans des modeles animaux experimentaux
AU2002367087A1 (en) * 2001-12-21 2003-07-15 7Tm Pharma A/S Method for the treatment of mc receptor related disorders with a chelate and/or a chelator
AU2002358469A1 (en) * 2001-12-21 2003-07-15 7Tm Pharma A/S Modified receptors for the discovery of therapeutic ligands
JP5265762B2 (ja) 2008-05-13 2013-08-14 ユニバーシティ・オブ・カンザス 金属抽出ペプチド（ｍａｐ）タグおよび関連する方法
WO2013181461A2 (fr) 2012-06-01 2013-12-05 University Of Kansas Peptide de capture de métal avec une activité superoxyde dismutase
CN110390997B (zh) * 2019-07-17 2023-05-30 成都火石创造科技有限公司 一种化学分子式拼接方法
US20230226214A1 (en) * 2020-06-24 2023-07-20 Lycia Therapeutics, Inc. Bifunctional bridging compositions for viral transduction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6027711A (en) * 1995-06-07 2000-02-22 Rhomed Incorporated Structurally determined metallo-constructs and applications
WO1996041169A1 (fr) * 1995-06-07 1996-12-19 Praecis Pharmaceuticals Incorporated Dosage biologique fonctionnel pour les agonistes et antagonistes des recepteurs couples de proteine g
AU4585197A (en) * 1996-09-20 1998-04-14 President And Fellows Of Harvard College Combinatorial approach for generating novel coordination complexes
JP2001521896A (ja) * 1997-10-31 2001-11-13 スミスクライン・ビーチャム・コーポレイション 新規な金属錯体
DE19909357A1 (de) * 1999-03-03 2000-09-07 Gerd Multhaup Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt
WO2001013112A1 (fr) * 1999-08-12 2001-02-22 Palatin Technologies, Inc. Constructions de metallopeptides de melanocortine, banques combinatoires et applications

Also Published As

Publication number Publication date
WO2001050127A2 (fr) 2001-07-12
AU2844901A (en) 2001-07-16
WO2001050127A8 (fr) 2004-02-19
WO2001050127A3 (fr) 2002-01-31
WO2001050127A9 (fr) 2002-09-12
EP1242824A2 (fr) 2002-09-25

Similar Documents

Publication Publication Date Title
US20020061599A1 (en) Method of identifying ligands of biological target molecules
Galandrin et al. The evasive nature of drug efficacy: implications for drug discovery
Wang et al. Structure‐Based Evolution of G Protein‐Biased μ‐Opioid Receptor Agonists
Gether Uncovering molecular mechanisms involved in activation of G protein-coupled receptors
Kenakin Drug efficacy at G protein–coupled receptors
Latek et al. G protein-coupled receptors—recent advances
George et al. G-protein-coupled receptor oligomerization and its potential for drug discovery
May et al. Allosteric modulation of G protein–coupled receptors
Ellis et al. The state of GPCR research in 2004
Li et al. Chemical synthesis of a full-length G-protein-coupled receptor β2-adrenergic receptor with defined modification patterns at the C-terminus
Heifetz et al. Fighting obesity with a sugar-based library: discovery of novel MCH-1R antagonists by a new computational–VAST approach for exploration of GPCR binding sites
Bernat et al. Boronic acids as probes for investigation of allosteric modulation of the chemokine receptor CXCR3
WO2003003008A1 (fr) Bibliotheques chimiques utiles aux procedes de decouvertes de medicaments
Schiedel et al. Prediction and targeting of interaction interfaces in G-protein coupled receptor oligomers
Hendrikse et al. Identification of small-molecule positive modulators of calcitonin-like receptor-based receptors
CA2395999A1 (fr) Methode permettant d'identifier des ligands de molecules biologiques cibles
Zheng et al. Biased agonists of the chemokine receptor CXCR3 differentially signal through Gαi: β-arrestin complexes
Lešnik et al. Fentanyl and the fluorinated fentanyl derivative NFEPP elicit distinct hydrogen-bond dynamics of the opioid receptor
Huber et al. Fluorescent ligands enable target engagement studies for the intracellular allosteric binding site of the chemokine receptor CXCR2
AU730875B2 (en) Functional bioassay for G-protein coupled receptor agonists and antagonists
Singh et al. Structural perspectives on the mechanism of signal activation, ligand selectivity and allosteric modulation in angiotensin receptors: IUPHAR Review 34
Anders et al. Direct identification of the agonist binding site in the human brain cholecystokininB receptor
Yang et al. Discovery of Small Molecule Agonist of Gonadotropin-Releasing Hormone Receptor (GnRH1R)
Desai et al. Molecular mechanism of action of triazolobenzodiazepinone agonists of the type 1 cholecystokinin receptor. Possible cooperativity across the receptor homodimeric complex
Cai et al. Cell Signaling and Trafficking of Human Melanocortin Receptors in Real Time Using Two‐photon Fluorescence and Confocal Laser Microscopy: Differentiation of Agonists and Antagonists

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead